Beam Therapeutics Inc. vs Johnson & Johnson — Stock Comparison
Beam Therapeutics Inc. (BEAM) and Johnson & Johnson (JNJ) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson scores ahead of Beam Therapeutics Inc. on Q·Score (7.1 vs 6.1 out of 10), led by Quality (9.3 vs 1.2) and Valuation (7 vs 6.2). Beam Therapeutics Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for BEAM (+57.2%) than for JNJ (+8.0%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-40% margin).
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
BEAM vs JNJ: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7.1/10 versus Beam Therapeutics Inc. (BEAM) at 6.1/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: BEAM or JNJ?
Beam Therapeutics Inc. (BEAM) scores higher on Growth (7.7/10 vs 5.1/10). Beam Therapeutics Inc. reports revenue growth (324.9% YoY) while Johnson & Johnson reports (9.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is BEAM or JNJ more attractively valued?
Johnson & Johnson (JNJ) scores higher on Valuation (7/10 vs 6.2/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about BEAM vs JNJ?
There are 15 analysts covering BEAM with a consensus price target of $51.07, and 23 analysts covering JNJ with a consensus target of $252.87. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: BEAM or JNJ?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 1.2/10). Net profit margin: BEAM at -40.2%, JNJ at 21.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: BEAM or JNJ?
Beam Therapeutics Inc. (BEAM) scores higher on Financial Health (9.2/10 vs 6.5/10). Market beta: BEAM at 2.20, JNJ at 0.26. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of BEAM and JNJ?
Beam Therapeutics Inc. (BEAM) has a market capitalisation of $3.3B, while Johnson & Johnson (JNJ) has a market cap of $563.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →